Literature DB >> 20466061

MHC class II transactivator negatively regulates RANKL-mediated osteoclast differentiation by downregulating NFATc1 and OSCAR.

Jung Ha Kim1, Kabsun Kim, Bang Ung Youn, Hye Mi Jin, Nacksung Kim.   

Abstract

Nuclear factor of activated T cells (NFAT) c1 plays a key role in receptor activator of nuclear factor kappaB ligand (RANKL)-induced osteoclast differentiation and function via induction of osteoclast-specific target genes including osteoclast-associated receptor (OSCAR), cathepsin K, and tartrate-resistant acid phosphatase. To elucidate which downstream target genes are regulated by NFATc1 during osteoclastogenesis, we used microarray analyses to examine gene expression profiles in the context of bone marrow-derived macrophages overexpressing a constitutively active form of NFATc1. Herein, we demonstrate that MHC class II transactivator (CIITA) is up-regulated downstream of NFATc1. Overexpression of CIITA in osteoclast precursors attenuates RANKL-induced osteoclast formation through down-regulation of NFATc1 and OSCAR. Epigenetic overexpression of CIITA regulates NFATc1 and OSCAR by competing with c-Fos and NFATc1 for CBP/p300 binding sites. Furthermore, silencing of CIITA by RNA interference in osteoclast precursors enhances osteoclast formation as well as NFATc1 and OSCAR expression. Taken together, our data reveal that CIITA can act as a modulator of RANKL-induced osteoclastogenesis. Copyright (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20466061     DOI: 10.1016/j.cellsig.2010.05.001

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  14 in total

1.  Interactions between the immune system and bone.

Authors:  Patrizia D'Amelio; Giorgia Fornelli; Ilaria Roato; Giovanni Carlo Isaia
Journal:  World J Orthop       Date:  2011-03-18

2.  Inactivation of glycogen synthase kinase-3β is required for osteoclast differentiation.

Authors:  Hyun Duk Jang; Ji Hye Shin; Doo Ri Park; Jin Hee Hong; Kwiyeom Yoon; Ryeojin Ko; Chang-Yong Ko; Han-Sung Kim; Daewon Jeong; Nacksung Kim; Soo Young Lee
Journal:  J Biol Chem       Date:  2011-09-23       Impact factor: 5.157

3.  Retinoic acid inhibits NFATc1 expression and osteoclast differentiation.

Authors:  Wayne Balkan; María Rodríguez-Gonzalez; Manhui Pang; Isabel Fernandez; Bruce R Troen
Journal:  J Bone Miner Metab       Date:  2011-03-08       Impact factor: 2.626

4.  CIITA: a master regulator of adaptive immunity shows its innate side in the bone.

Authors:  Mary C Nakamura
Journal:  J Bone Miner Res       Date:  2014-02       Impact factor: 6.741

5.  The role of the immune system in the physiopathology of osteoporosis.

Authors:  Valentina Cagnetta; Vittorio Patella
Journal:  Clin Cases Miner Bone Metab       Date:  2012-09-30

Review 6.  Bone-immune cell crosstalk: bone diseases.

Authors:  Giorgio Mori; Patrizia D'Amelio; Roberta Faccio; Giacomina Brunetti
Journal:  J Immunol Res       Date:  2015-04-27       Impact factor: 4.818

7.  HLA alleles association with changes in bone mineral density in HIV-1-infected adults changing treatment to tenofovir-emtricitabine or abacavir-lamivudine.

Authors:  Hila Haskelberg; Damien V Cordery; Janaki Amin; Anthony D Kelleher; David A Cooper; Sean Emery
Journal:  PLoS One       Date:  2014-03-28       Impact factor: 3.240

8.  Gene expression profiling in osteoclast precursors by insulin using microarray analysis.

Authors:  Hong Sung Kim; Na Kyung Lee
Journal:  Mol Cells       Date:  2014-11-05       Impact factor: 5.034

9.  PKCβ positively regulates RANKL-induced osteoclastogenesis by inactivating GSK-3β.

Authors:  Jihye Shin; Hyunduk Jang; Jingjing Lin; Soo Young Lee
Journal:  Mol Cells       Date:  2014-09-26       Impact factor: 5.034

10.  Polymorphisms in the inflammatory genes CIITA, CLEC16A and IFNG influence BMD, bone loss and fracture in elderly women.

Authors:  Maria Swanberg; Fiona E McGuigan; Kaisa K Ivaska; Paul Gerdhem; Kristina Åkesson
Journal:  PLoS One       Date:  2012-10-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.